12 Most Promising Biotech Stocks According to Wall Street Analysts

8. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Analyst Upside: 45.22% 

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands eighth among the most promising stocks according to Wall Street analysts. The company is focused on developing life-changing medicines for serious diseases, including eye conditions, cancer, inflammation, and rare genetic disorders.  The company’s cutting-edge VelociSuite technology, which speeds up drug research and genetic medicine development and aids in converting scientific discoveries into practical therapies, is what sets it apart.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported $3.8 billion in revenue in Q4 2024, a 10% increase over the same period the year before. With $14.2 billion in revenue for the entire year, it earned $1.4 billion in net income. The company’s strong financial position was demonstrated by its $3.7 billion in free cash flow and its remarkable 86% gross margin.

The corporation’s expansion was driven by important products like EYLEA, Libtayo, and Dupixent. With over a million patients treated globally, dupixent is still a huge success and may find new applications. In the meantime, the business is developing novel therapies for lymphoma and multiple myeloma that may increase its market share in oncology.

Notwithstanding its achievements, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) still faces difficulties in the anti-VEGF market, as EYLEA sales are being impacted by growing biosimilar competition. The business must manage these demands while keeping its attention on growth and innovation.